Our latest articles
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Replimune’s melanoma success looks more than skin deep
A highly respectable response rate with the company’s oncolytic virus bodes well in the post-checkpoint inhibitor setting.
Precision pays off for Prometheus
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
Gossamer unravels
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
Amgen tries something new in obesity
Early data are promising, but the upcoming phase 2 trial has questions to answer.
Boston’s struggle with obesity
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
CTAD 2022 – Lexeo takes baby steps towards Alzheimer’s gene therapy
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
